E-1-(but-2-en-1-yloxy)-4-(tert-butyl)benzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: E-1-(but-2-en-1-yloxy)-4-(tert-butyl)benzene
• 英文别名: 1-[(E)-but-2-enoxy]-4-tert-butylbenzene
• 化学式: C₁₄H₂₀O
• 分子量: 204.312
• InChiKey: VPPFQEKTHSQQCE-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  E-1-(but-2-en-1-yloxy)-4-(tert-butyl)benzene 在 bis(1,5-cyclooctadiene)nickel (0) 、 二苯基硅烷 、 potassium carbonate 、 4,4'-二叔丁基-2,2'-二吡啶 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 32.0h， 生成 4-叔丁基苯酚
  参考文献：
  名称：

  镍催化芳基烯丙基醚与氢硅烷的脱烯丙基化

  摘要：

  以市售Ni(COD)为催化剂前驱体、简单取代联吡啶为配体和空气稳定的氢硅烷，开发了一种高效、温和的芳基烯丙基醚催化脱烯丙基化方法。该工艺与多种官能团兼容，并且能够以优异的产率和选择性获得所需的苯酚产品。此外，通过检测或分离关键中间体，机制研究证实脱烯丙基化经历了-烯丙基镍中间体途径。

  DOI：

  10.1016/j.tetlet.2021.153341
• 作为产物：
  描述：

  1-(tert-butyl)-4-(cinnamyloxy)benzene 在 bis(1,5-cyclooctadiene)nickel (0) 、 1,1,3,3-四甲基二硅氧烷 、 二苯基硅烷 、 potassium carbonate 、 4,4'-二叔丁基-2,2'-二吡啶 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 44.0h， 生成 E-1-(but-2-en-1-yloxy)-4-(tert-butyl)benzene
  参考文献：
  名称：

  镍催化芳基烯丙基醚与氢硅烷的脱烯丙基化

  摘要：

  以市售Ni(COD)为催化剂前驱体、简单取代联吡啶为配体和空气稳定的氢硅烷，开发了一种高效、温和的芳基烯丙基醚催化脱烯丙基化方法。该工艺与多种官能团兼容，并且能够以优异的产率和选择性获得所需的苯酚产品。此外，通过检测或分离关键中间体，机制研究证实脱烯丙基化经历了-烯丙基镍中间体途径。

  DOI：

  10.1016/j.tetlet.2021.153341

文献信息

• Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
  申请人：Hummersone Marc Geoffrey

  公开号：US20080194546A1

  公开（公告）日：2008-08-14

  There is provided a compound of formula I: wherein: one or two of X 5 , X 6 and X 8 is N, and the others are CH; R 7 is selected from halo, OR O1 , SR S1 , NR N1 R N2 , NR N7a C(═O)R C1 , NR N7b SO 2 R S2a , an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 5-20 aryl group, where R O1 and R S1 are selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N1 and R N2 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 5-20 aryl group or R N1 and R N2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R C1 is selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 1-7 alkyl group or NR N8 R N9 , where R N8 and R N9 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 5-20 aryl group or R N8 and R N9 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R S2a is selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N7a and R N7b are selected from H and a C 1-4 alkyl group; R N3 and R N4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms; R 2 is selected from H, halo, OR O2 , SR S2b , NR N5 R N6 , an optionally substituted C 5-20 heteroaryl group, and an optionally substituted C 5-20 aryl group, wherein R O2 and R S2b are selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N5 and R N6 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, and an optionally substituted C 5-20 aryl group, or R N5 and R N6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, or a pharmaceutically acceptable salt thereof, with the proviso that when R 2 is unsubstituted morpholino. R N3 and R N4 together with the nitrogen atom to which they are attached form an unsubstituted morpholino and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not N and X 8 is not CH, or X 6 is not CH and X 8 is not N, and when R 2 is unsubstituted piperidinyl, R N3 and R N4 together with the nitrogen atom to which they are attached form an unsubstituted piperidinyl and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not CH and X is not N. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  提供了一种化合物，其化学式为I：其中：X5、X6和X8中的一个或两个是N，其余为CH；R7选自卤素、ORO1、SRS1、NRN1RN2、NRN7aC（═O）RC1、NRN7bSO2RS2a、可选取代的C5-20杂环芳基基团或可选取代的C5-20芳基基团，其中RO1和RS1选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN1和RN2独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团、可选取代的C5-20芳基基团或RN1和RN2与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；RC1选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团、可选取代的C1-7烷基基团或NRN8RN9，其中RN8和RN9独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团、可选取代的C5-20芳基基团或RN8和RN9与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；RS2a选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN7a和RN7b选自H和C1-4烷基基团；RN3和RN4与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；R2选自H、卤素、ORO2、SRS2b、NRN5RN6、可选取代的C5-20杂环芳基基团和可选取代的C5-20芳基基团，其中RO2和RS2b选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN5和RN6独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团和可选取代的C5-20芳基基团，或RN5和RN6与它们所连接的氮原子一起形成含有3至8个环原子的杂环环，或其药学上可接受的盐，但当R2为未取代的吗啡啶基时，RN3和RN4与它们所连接的氮原子一起形成未取代的吗啡啶基，R7为未取代的苯基，且X5为CH时，X6不是N且X8不是CH，或X6不是CH且X8不是N，当R2为未取代的哌啶基时，RN3和RN4与它们所连接的氮原子一起形成未取代的哌啶基，R7为未取代的苯基，且X5为CH时，X6不是CH且X不是N。还提供了制造化合物I的方法，以及将化合物I用作药物治疗癌症的用途。
• Nickel-catalyzed deallylation of aryl allyl ethers with hydrosilanes
  作者：Jingyang Wang、Yu Wang、Guangni Ding、Xiaoyu Wu、Liqun Yang、Sijie Fan、Zhaoguo Zhang、Xiaomin Xie

  DOI：10.1016/j.tetlet.2021.153341

  日期：2021.9

  An efficient and mild catalytic deallylation method of aryl allyl ethers is developed, with commercially available Ni(COD) as catalyst precursor, simple substituted bipyridine as ligand and air-stable hydrosilanes. The process is compatible with a variety of functional groups and the desired phenol products can be obtained with excellent yields and selectivity. Besides, by detection or isolation of

  以市售Ni(COD)为催化剂前驱体、简单取代联吡啶为配体和空气稳定的氢硅烷，开发了一种高效、温和的芳基烯丙基醚催化脱烯丙基化方法。该工艺与多种官能团兼容，并且能够以优异的产率和选择性获得所需的苯酚产品。此外，通过检测或分离关键中间体，机制研究证实脱烯丙基化经历了-烯丙基镍中间体途径。